These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 8804911

  • 1. Antianginal effects of FR144420, a novel slow nitric oxide-releasing agent.
    Hirasawa Y, Sugimoto T, Fukuyama S, Kato Y, Takamatu H, Ohno M, Nishino S, Kato M, Maeda K, Seki J, Kita Y.
    Eur J Pharmacol; 1996 May 06; 303(1-2):55-9. PubMed ID: 8804911
    [Abstract] [Full Text] [Related]

  • 2. FR144420, a novel, slow, nitric oxide-releasing agent.
    Kita Y, Ohkubo K, Hirasawa Y, Katayama Y, Ohno M, Nishino S, Kato M, Yoshida K.
    Eur J Pharmacol; 1995 Mar 06; 275(2):125-30. PubMed ID: 7796846
    [Abstract] [Full Text] [Related]

  • 3. Antianginal effects of FK409, a new spontaneous NO releaser.
    Kita Y, Ozaki R, Sakai S, Sugimoto T, Hirasawa Y, Ohtsuka M, Senoh H, Yoshida K, Maeda K.
    Br J Pharmacol; 1994 Dec 06; 113(4):1137-40. PubMed ID: 7889266
    [Abstract] [Full Text] [Related]

  • 4. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
    Kita Y, Hirasawa Y, Fukuyama S, Ohkubo K, Kato Y, Takamatsu H, Ohno M, Nishino S, Kato M, Seki J.
    J Pharmacol Exp Ther; 1996 Feb 06; 276(2):421-5. PubMed ID: 8632305
    [Abstract] [Full Text] [Related]

  • 5. Effect of FK409, a novel nitric oxide donor, on acute experimental myocardial ischemia.
    Isono T, Sato N, Koibuchi Y, Sakai S, Yamamoto T, Ozaki R, Mori J, Kohsaka M, Ohtsuka M.
    Jpn J Pharmacol; 1993 Jul 06; 62(3):315-24. PubMed ID: 8411778
    [Abstract] [Full Text] [Related]

  • 6. In vitro effects of new generation fungal derived nitric oxide donors on rabbit basilar artery.
    Islam MS, Ohkuma H, Kimura M, Suzuki S.
    Neurol Med Chir (Tokyo); 2003 Apr 06; 43(4):175-80; discussion 180. PubMed ID: 12760495
    [Abstract] [Full Text] [Related]

  • 7. Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats.
    Sasaki T, Maruyama H, Kase Y, Takeda S, Aburada M.
    Biol Pharm Bull; 2005 May 06; 28(5):811-6. PubMed ID: 15863884
    [Abstract] [Full Text] [Related]

  • 8. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats.
    Kita Y, Hirasawa Y, Kato Y, Ohkubo K, Ohno M, Nishino S, Kato M, Fukuyama S.
    J Cardiovasc Pharmacol; 1997 Aug 06; 30(2):223-8. PubMed ID: 9269950
    [Abstract] [Full Text] [Related]

  • 9. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409.
    Hirasawa Y, Kato Y, Fukuyama S, Ohno M, Nishino S, Kato M, Kita Y.
    Thromb Haemost; 1998 Mar 06; 79(3):620-4. PubMed ID: 9531052
    [Abstract] [Full Text] [Related]

  • 10. Renal hemodynamic and excretory responses in anesthetized rats to FK409, a novel nitric oxide donor.
    Urabe K, Matsumura Y, Nishiura M, Maeda K, Morimoto S.
    Eur J Pharmacol; 1997 Feb 26; 321(2):195-200. PubMed ID: 9063688
    [Abstract] [Full Text] [Related]

  • 11. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
    Hirasawa Y, Nishio M, Maeda K, Yoshida K, Kita Y.
    Eur J Pharmacol; 1995 Jan 05; 272(1):39-43. PubMed ID: 7713147
    [Abstract] [Full Text] [Related]

  • 12. Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.
    Kita Y, Sugimoto T, Hirasawa Y, Yoshida K, Maeda K.
    Br J Pharmacol; 1994 Sep 05; 113(1):5-6. PubMed ID: 7812632
    [Abstract] [Full Text] [Related]

  • 13. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats.
    Matsumura Y, Nishiura M, Deguchi S, Hashimoto N, Ogawa T, Seo R.
    J Pharmacol Exp Ther; 1998 Dec 05; 287(3):1084-91. PubMed ID: 9864296
    [Abstract] [Full Text] [Related]

  • 14. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
    Kita Y, Hirasawa Y, Maeda K, Nishio M, Yoshida K.
    Eur J Pharmacol; 1994 May 12; 257(1-2):123-30. PubMed ID: 8082692
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
    Fukuyama S, Hirasawa Y, Kato Y, Nishio M, Ohno M, Nishino S, Maeda K, Kato M, Kita Y.
    J Pharmacol Exp Ther; 1997 Jul 12; 282(1):236-42. PubMed ID: 9223559
    [Abstract] [Full Text] [Related]

  • 16. Antiplatelet activities of FK409, a new spontaneous NO releaser.
    Kita Y, Hirasawa Y, Yoshida K, Maeda K.
    Br J Pharmacol; 1994 Oct 12; 113(2):385-8. PubMed ID: 7834188
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic mechanisms of the antianginal action of a novel vasodilator FK409 in dynamic exercise-induced angina.
    Yokota M, Matsunami T, Kodama Y, Sobue T, Nishinaka Y, Iwase M, Miyahara T, Koide M, Saito H, Shibata S.
    J Cardiovasc Pharmacol; 1993 Mar 12; 21(3):412-22. PubMed ID: 7681502
    [Abstract] [Full Text] [Related]

  • 18. Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats.
    Kita Y, Fukuyama S, Hirasawa Y.
    Jpn J Pharmacol; 1995 Sep 12; 69(1):69-74. PubMed ID: 8847834
    [Abstract] [Full Text] [Related]

  • 19. Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409.
    Isono T, Sato N, Yamamoto T, Sawada T, Yamazaki S, Miura S, Furuichi A, Ozaki R, Koibuchi Y, Ohtsuka M.
    Eur J Pharmacol; 1994 Aug 01; 260(2-3):163-8. PubMed ID: 7988640
    [Abstract] [Full Text] [Related]

  • 20. FK409 inhibits both local and remote organ damage after intestinal ischaemia.
    Kalia N, Brown NJ, Hopkinson K, Stephenson TJ, Wood RF, Pockley AG.
    J Pathol; 2002 Aug 01; 197(5):595-602. PubMed ID: 12210078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.